Hiroki Oyama

ORCID: 0000-0003-3591-821X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Gallbladder and Bile Duct Disorders
  • Pancreatitis Pathology and Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Esophageal and GI Pathology
  • Neuroendocrine Tumor Research Advances
  • Pediatric Hepatobiliary Diseases and Treatments
  • Colorectal Cancer Screening and Detection
  • Biliary and Gastrointestinal Fistulas
  • Nutrition and Health in Aging
  • Cancer Genomics and Diagnostics
  • Oral health in cancer treatment
  • Scoliosis diagnosis and treatment
  • Spine and Intervertebral Disc Pathology
  • Gastrointestinal disorders and treatments
  • Shoulder Injury and Treatment
  • Head and Neck Cancer Studies
  • Frailty in Older Adults
  • Lower Extremity Biomechanics and Pathologies
  • Epigenetics and DNA Methylation
  • Sports injuries and prevention
  • Multiple Myeloma Research and Treatments
  • Lymphatic Disorders and Treatments
  • Cancer Research and Treatment
  • Peripheral Nerve Disorders

The University of Tokyo
2015-2025

Nagoya University
2023-2025

Japanese Red Cross Medical Center
2020-2025

Konan Kosei Hospital
2024

Tokyo City University
2019

Bunkyo University
2019

Anjo Kosei Hospital
2019

Hokkaido University
2015

NTT Medical Center
2015

Nippon Medical School
2015

During liver development, hepatoblasts and non-parenchymal cells (NPCs) such as sinusoidal endothelial (LSECs) hepatic stellate (HSCs) constitute the bud where they proliferate differentiate. Accordingly, we reasoned that NPCs would support maturation of hepatocytes derived from human induced pluripotent stem (hiPSCs), which usually exhibit limited functions. We found transforming growth factor β Rho signaling pathways, respectively, regulated proliferation LSEC HSC progenitors isolated...

10.1016/j.stemcr.2017.06.010 article EN cc-by-nc-nd Stem Cell Reports 2017-07-27

Objective Current guidelines recommend long-term image-based surveillance for patients with low-risk intraductal papillary mucinous neoplasms (IPMNs). This simulation study aimed to examine the comparative cost-effectiveness of continued versus discontinued at different ages and define optimal age stop surveillance. Design We constructed a Markov model lifetime horizon simulate clinical course IPMNs receiving imaging-based calculated incremental ratios (ICERs) surveillance, stratified by sex...

10.1136/gutjnl-2023-330329 article EN Gut 2024-01-29

Background Cyst size, its growth rate, and diameter of the main pancreatic duct (MPD) are all associated with carcinoma prevalence in intraductal papillary mucinous neoplasms (IPMNs). Objective To examine above factors relation to future risk incident individuals IPMNs harbouring no high-risk stigmata. Design In a prospective longitudinal cohort, we analysed 2549 patients IPMNs. A multivariable cause-specific Cox proportional hazards regression model was built estimate HRs for carcinoma....

10.1136/gutjnl-2024-333259 article EN Gut 2025-01-27

Purpose: To explore the clinical outcomes associated with screw loosening after S2 alar-iliac (SAI) fixation for adult spinal deformity (ASD). Overview of literature: SAI is widely used in ASD corrective surgery; despite biomechanical advantages this screw, complications such as remain a significant concern. Methods: We retrospectively reviewed 27 patients undergoing surgery using distal point at single institution between February 2013 and 2018. Patients were divided into non-loosening (N)...

10.3390/jcm14061881 article EN Journal of Clinical Medicine 2025-03-11

Endoscopic retrograde cholangiopancreatography (ERCP) is widely utilized to manage pancreatobiliary diseases, but post-ERCP pancreatitis (PEP) an unsolved issue. Although post-procedural elevation of serum amylase level useful for early prediction PEP, effectiveness interventions hyperamylasemia has not been evaluated. Therefore, we conducted this study elucidate the role additional hydration in cases with after ERCP. This retrospective included patients without a previous history ERCP who...

10.1097/mpa.0000000000002493 article EN Pancreas 2025-03-25

Abstract Background Studies have demonstrated a prognostic role of sarcopenia ( i.e. , loss skeletal muscle volume and functionality) in patients with various cancer types. In biliary tract cancer, the quantity quality muscles their serial changes not been fully investigated relation to survival outcomes. Methods We identified 386 unresectable or recurrent calculated index (SMI) density (SMD) estimate muscular quality, respectively, based on computed tomography images. Using Cox regression...

10.1007/s10147-023-02466-z article EN cc-by International Journal of Clinical Oncology 2024-02-06

Patients with pancreatic cancer often have cachexia at diagnosis. Recent studies suggested that loss of skeletal muscle mass was related to cachexia, which hindered continuance chemotherapy and could be one prognostic factors in cancer, however the association remains unclear patients receiving gemcitabine nab-paclitaxel (GnP).We retrospectively studied 138 unresectable first-line GnP University Tokyo from January 2015 September 2020. We calculated body composition CT images before initial...

10.1007/s00520-023-07659-w article EN cc-by Supportive Care in Cancer 2023-03-01

Balloon endoscopy-assisted endoscopic retrograde cholangiopancreatography (BE-ERCP) is an emerging procedure for pancreatobiliary diseases in patients with surgically altered anatomy. However, data on BE-ERCP hepatolithiasis after hepaticojejunostomy (HJS) are still limited.

10.1007/s00464-024-10738-6 article EN cc-by Surgical Endoscopy 2024-03-07

Kazunaga Ishigaki, Yousuke Nakai, Hiroki Oyama, Sachiko Kanai, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Ryunosuke Hakuta, Kei Saito, Tomotaka Naminatsu Takahara, Tsuyoshi Hamada, Suguru Mizuno, Hirofumi Kogure, Minoru Tada, Hiroyuki Isayama, and Kazuhiko Koike. Gut Liver 2020;14:817-25. https://doi.org/10.5009/gnl19171

10.5009/gnl19171 article SW cc-by-nc Gut and Liver 2020-05-27

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to the difficulty of its diagnosis. Because human satellite II (HSATII) RNA, repeat is highly and specifically expressed in PDAC, serum HSATII RNA level may be biomarker PDAC. To measure with high sensitivity reproducibility, we previously developed convenient method, tandem amplification by nuclease protection (TRAP) combined droplet digital PCR (ddPCR). Here, refined original method simultaneously measuring miR-21-5p enhance...

10.1016/j.isci.2023.106021 article EN cc-by-nc-nd iScience 2023-01-19

Abstract Background Trajectories of serological and morphological signatures have not been documented in pancreatic carcinogenesis related to intraductal papillary mucinous neoplasms (IPMNs). Methods Using a prospective cohort 3437 IPMN patients, we identified 100 patients who developed carcinomas during long-term surveillance. We examined serial changes blood markers (carbohydrate antigen 19-9 [CA19-9], hemoglobin A1c [HbA1c], enzymes) features (worrisome high-risk stigmata) the...

10.1007/s00535-023-02028-0 article EN cc-by Journal of Gastroenterology 2023-07-29

Abstract Background and study aims Pancreatitis is a potentially lethal adverse event of endoscopic transpapillary placement self-expandable metal stent (SEMS) for malignant biliary obstruction (MBO). Deep learning-based image recognition has not been investigated in predicting pancreatitis this setting. Patients methods We included 70 patients who underwent SEMS nonresectable distal MBO. constructed convolutional neural network (CNN) model prediction using series pre-procedure computed...

10.1055/a-2298-0147 article EN cc-by-nc-nd Endoscopy International Open 2024-04-02

Abstract Background Since homologous recombination deficiency (HRD) is relatively uncommon in pancreatic cancer (PC), its impact on time-to-treatment failure (TTF) among patients undergoing systemic chemotherapy for unresectable and recurrent PC remains uncertain. Methods Among with enrolled the Center Cancer Genomics Advanced Therapeutics (C-CAT) database by July 2023, a total of 1394 who underwent first-line either gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX (FFX) received...

10.1007/s00535-024-02173-0 article EN cc-by Journal of Gastroenterology 2024-11-21
Coming Soon ...